CoChat
Sign Up
Cited by 19Bone health and osteoporosis researchBone health and treatmentsBone Metabolism and Diseases

Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids

Devogelaer, J.-P., Sambrook, P., Reid, D. M., Goemaere, S., Ish-Shalom, S., Collette, J., Su, G., Bucci-Rechtweg, C. +2 more·2013·Rheumatology
DOI 10.1093/rheumatology/kes410
Open this paper in CoChat — free account

Abstract

OBJECTIVE: Long-term glucocorticoid use is accompanied by rapid bone loss; however, early treatment with bisphosphonates prevents bone loss and reduces fracture risk. The aim of this study was to examine the effects of two bisphosphonates, i.v. zoledronic acid (ZOL) versus oral risedronate (RIS), on bone turnover markers (BTMs) in subjects with glucocorticoid-induced osteoporosis (GIO). METHODS: Patients were randomly stratified according to the duration of pre-study glucocorticoid therapy [prevention subpopulation (ZOL, n = 144; RIS, n = 144) ≤3 months, treatment subpopulation (ZOL, n = 272; RIS, n = 273) >3 months]. Changes in β-C-terminal telopeptides of type 1 collagen (β-CTx), N-terminal telopeptide of type I collagen (NTx), procollagen type 1 N-terminal propeptide (P1NP) and bone-specific alkaline phosphatase (BSAP) from baseline were measured on day 10 and months 3, 6 and 12. RESULTS: At most time points, there were significantly greater reductions (P < 0.05) in the concentrations of serum β-CTx, P1NP and BSAP and urine NTx in subjects on ZOL compared with RIS in both males and females of the treatment and prevention subpopulations. In pre- and post-menopausal women, there were significantly greater reductions in the concentrations of BTMs with ZOL compared with RIS. At 12 months, ZOL had significantly greater reductions compared with RIS (P < 0.05) for β-CTx, P1NP, BSAP and NTx levels, independent of glucocorticoid dose. CONCLUSIONS: Once-yearly i.v. infusion of ZOL 5 mg was well tolerated in different subgroups of GIO patients. ZOL was non-inferior to RIS and even superior to RIS in the response of BTMs in GIO patients. TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov, NCT00100620.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/rheumatology/kes410

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In clinical practice, both bisphosphonates and PTH increase spine BMD to a greater extent than hip BMD.

    “In clinical practice, both bisphosphonates and PTH increase the spine BMD to a greater extent than the hip BMD [12, 14, 47, 50-53].”

    From Prevention of glucocorticoid induced bone changes with beta-ecdysone (2015) · cites this paper as [47]

  • The anabolic agent hPTH (1-34) is superior to bisphosphonates in increasing spine and hip BMD and reduces the incidence of new vertebral fractures in glucocorticoid-induced osteoporosis populations for both men and women.

    “In support of this notion, it is reported that anabolic agent, hPTH (1-34), is superior to bisphosphonates in increasing spine and hip BMD and reduces the incidence of new vertebral fractures in glucocorticoid-induced osteoporosis (GIOP) populations for both men and women [11, 47-49].”

    From Prevention of glucocorticoid induced bone changes with beta-ecdysone (2015) · cites this paper as [47]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 6

  1. Van Staa TP, Abenhaim L, Cooper C et al. The use of a large pharmacoepidemiological database to study ex- posure to oral corticosteroids and risk of fractures: valid- ation of study population and results. Pharmacoepidemiol Drug Saf 2000;9:35966.
  2. Cohen S, Levy RM, Keller M et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999;42:230918.
  3. Adachi JD, Saag KG, Delmas PD et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving GC: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001; 44:20211.
  4. Black DM, Delmas PD, Eastell R et al. Once-yearly zole- dronic acid for treatment of postmenopausal osteopor- osis. N Engl J Med 2007;356:180922.
  5. Bergmann P, Body JJ, Boonen S et al. Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphospho- nate treatment in osteoporosis. Int J Clin Pract 2009;63: 1926.
  6. Foster-Swanson A, Swartzentruber M, Roberts P et al. Reference interval studies of the rate-blanked creatinine/ Jaffe method on BM/Hitachi systems in six US labora- tories [abstract]. Clin Chem 1994;40:1057.

Cited by

Sorted by citations

Related

Authors
Devogelaer, J.-P., Sambrook, P., Reid, D. M., Goemaere, S., Ish-Shalom, S., Collette, J., Su, G., Bucci-Rechtweg, C., Papanastasiou, P., & Reginster, J.-Y.
Affiliations
  • UCLouvain (BE)
  • The University of Sydney (AU)
ORCID
Venue
Rheumatology
Publisher
Oxford University Press (OUP)
Published
2013-01-30
Volume
52
Issue
6
Pages
1058-1069
ISSN
  • 1462-0324 (ISSN-L)
  • 1462-0332
DOI
10.1093/rheumatology/kes410
OpenAlex
W2100559874
Cited by
19
References
46
Citations by year
2026: 1 · 2024: 1 · 2020: 2 · 2018: 3 · 2017: 1 · 2016: 4 · 2015: 5 · 2014: 1 · 2013: 1
FWCI
3.75
Type
journal article
Language
en
Open access
closed
Locations
  • Lara D. Veeken (publishedVersion)
  • PubMed (publishedVersion)
  • reroDoc Digital Library (submittedVersion)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion)
  • DIAL (Catholic University of Leuven) (submittedVersion)
  • ORBi (University of Liège) (submittedVersion)
Topics
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Oncology › Bone health and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Keywords
glucocorticoid-induced osteoporosis, zoledronic acid, risedronate, bisphosphonates, bone turnover markers, intravenous infusion, oral administration, β-CTX, NTX, P1NP, bone-specific alkaline phosphatase, menopause, non-inferiority
MeSH terms
Risedronic Acid, Zoledronic Acid, Administration, Oral, Adolescent, Adult, Aged, Aged, 80 and over, Diphosphonates, Drug Administration Schedule, Drug Therapy, Combination, Female, Glucocorticoids, Humans, Imidazoles, Infusions, Intravenous, Male, Middle Aged, Osteoporosis, Prednisone, Etidronic Acid, Treatment Outcome, Bone Density Conservation Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review